Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

RMJ. 2010; 35(2): 165-167


Use of Injection Solcoseryl for the treatment of oligohydramnios

Khurshid Shabbir Raja, Huma Tasleem.




Abstract

Objectives
To assess the efficacy of drug hemodialysate (solcoseryl) on liquor volume in intrauterine growth restricted (IUGR) babies and their outcome in view of APGAR score and their health status.
Patients and Methods
In this study, a total of 70 patients with IUGR were included and it was carried out at Shifa International Hospital and Shifa Foundation Community Health Clinic Islamabad from January 2006 to December 2008. The patients were divided in two groups with 35 in each group. In group one, no infusion of solcoseryl was given, only left lateral position and plenty of fluids were advised (Conventional therapy). In group two, 10 mg of solcoseryl was given in 500 ml of normal saline at the rate of 125 ml/hour per day after 28 weeks of gestation (Interventional therapy). If the patient was hypertensive, 500 ml of Dextrose water was used instead of normal saline. Minimum one dose and maximum 28 doses were used. Both groups were compared with level of amniotic fluid index before and after the treatment.
Results
Out of 70 patients, frequency of IUGR in group one it was 6.83±2.24, (t = -3.28, 95% CI, -2.89 -.704),
Conclusion
Solcoseryl is the drug of choice in pregnant women with IUGR, especially after twenty eight week of gestation.

Key words: Solcoseryl, oligohyramnios, IUGR.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.